Thanks for the update Sam.
The biotech industry group as a whole got creamed during the recent correction. Many traders are still short this group (IBB short interest ratio = 7.90), setting up squeeze conditions as investors move more towards risky/speculative investments.
AMRN has mirrored the group with its latest trading behavior and all things seem to be in sync: high short interest ratio, bullish squeeze pattern, a recovering general market, recovering industry group, powerful fundamental news coming.